Pharmacological Properties of DOV 315,090, an ocinaplon metabolite. 2008

Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
Laboratory of Molecular Neurobiology, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, USA.

BACKGROUND Compounds targeting the benzodiazepine binding site of the GABAA-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre-anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABAA-R subtypes. If this hypothesis is correct, then it may be possible to develop compounds targeting particular GABAA-R subtypes as, for example, selective anxiolytics with a diminished side effect profile. The pyrazolo[1,5-a]-pyrimidine ocinaplon is anxioselective in both preclinical studies and in patients with generalized anxiety disorder, but does not exhibit the selectivity between alpha1/alpha2-containing receptors for an anxioselective that is predicted by studies using transgenic mice. RESULTS We hypothesized that the pharmacological properties of ocinaplon in vivo might be influenced by an active biotransformation product with greater selectivity for the alpha2 subunit relative to alpha1. One hour after administration of ocinaplon, the plasma concentration of its primary biotransformation product, DOV 315,090, is 38% of the parent compound. The pharmacological properties of DOV 315,090 were assessed using radioligand binding studies and two-electrode voltage clamp electrophysiology. We report that DOV 315,090 possesses modulatory activity at GABAA-Rs, but that its selectivity profile is similar to that of ocinaplon. CONCLUSIONS These findings imply that DOV 315,090 could contribute to the action of ocinaplon in vivo, but that the anxioselective properties of ocinaplon cannot be readily explained by a subtype selective effect/action of DOV 315,090. Further inquiry is required to identify the extent to which different subtypes are involved in the anxiolytic and other pharmacological effects of GABAA-R modulators.

UI MeSH Term Description Entries
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003497 Cyclic N-Oxides Heterocyclic compounds in which an oxygen is attached to a cyclic nitrogen. Heterocyclic N-Oxides,Cyclic N Oxides,Heterocyclic N Oxides,N Oxides, Cyclic,N-Oxides, Cyclic,N-Oxides, Heterocyclic,Oxides, Cyclic N
D003975 Diazepam A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity. 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one,Apaurin,Diazemuls,Faustan,Relanium,Seduxen,Sibazon,Stesolid,Valium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014151 Anti-Anxiety Agents Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. Anti-Anxiety Agent,Anti-Anxiety Drug,Anxiolytic,Anxiolytic Agent,Anxiolytic Agents,Tranquilizing Agents, Minor,Anti-Anxiety Drugs,Anti-Anxiety Effect,Anti-Anxiety Effects,Antianxiety Effect,Antianxiety Effects,Anxiolytic Effect,Anxiolytic Effects,Anxiolytics,Tranquillizing Agents, Minor,Agent, Anti-Anxiety,Agent, Anxiolytic,Agents, Anti-Anxiety,Agents, Anxiolytic,Agents, Minor Tranquilizing,Agents, Minor Tranquillizing,Anti Anxiety Agent,Anti Anxiety Agents,Anti Anxiety Drug,Anti Anxiety Drugs,Anti Anxiety Effect,Anti Anxiety Effects,Drug, Anti-Anxiety,Drugs, Anti-Anxiety,Effect, Anti-Anxiety,Effect, Antianxiety,Effect, Anxiolytic,Effects, Anti-Anxiety,Effects, Antianxiety,Effects, Anxiolytic,Minor Tranquilizing Agents,Minor Tranquillizing Agents
D014982 Xenopus laevis The commonest and widest ranging species of the clawed "frog" (Xenopus) in Africa. This species is used extensively in research. There is now a significant population in California derived from escaped laboratory animals. Platanna,X. laevis,Platannas,X. laevi

Related Publications

Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
April 2010, CNS neuroscience & therapeutics,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
February 1981, Chemico-biological interactions,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
January 2006, Cellular and molecular neurobiology,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
October 1992, Arzneimittel-Forschung,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
February 2013, Current biology : CB,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
December 1955, Nature,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
August 1991, Journal of pharmaceutical sciences,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
July 2001, Seminars in nuclear medicine,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
May 1981, Acta pharmacologica et toxicologica,
Dmytro Berezhnoy, and Maria C Gravielle, and Scott Downing, and Emmanuel Kostakis, and Anthony S Basile, and Phil Skolnick, and Terrell T Gibbs, and David H Farb
May 1982, European journal of pharmacology,
Copied contents to your clipboard!